Artisan Partners Limited Partnership I Mab Transaction History

Artisan Partners Limited Partnership

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$8.27 - $18.43 $1.59 Million - $3.55 Million	-192,574 Reduced 13.56%	1,227,651 $13.9 Million
Q1 2022 May 13, 2022	BUY	$12.54 - $46.93 $12.7 Million - $47.7 Million	1,016,180 Added 251.5%	1,420,225 $23.1 Million
Q4 2021 Feb 11, 2022	SELL	$45.28 - $74.5 $1.85 Million - $3.05 Million	-40,948 Reduced 9.2%	404,045 $19.1 Million
Q3 2021 Nov 12, 2021	SELL	$57.18 - $84.43 $1.08 Million - $1.6 Million	-18,946 Reduced 4.08%	444,993 $32.3 Million
Q2 2021 Aug 12, 2021	SELL	$47.86 - $83.95 $19.8 Million - $34.8 Million	-413,952 Reduced 47.15%	463,939 $38.9 Million
Q1 2021 May 11, 2021	BUY	$44.38 - $63.97 $939,924 - $1.35 Million	21,179 Added 2.47%	877,891 $42.6 Million
Q4 2020 Feb 10, 2021	BUY	$32.94 - $47.15 $7.03 Million - $10.1 Million	213,522 Added 33.2%	856,712 $40.4 Million
Q3 2020 Nov 12, 2020	BUY	$27.46 - $47.03 $4.09 Million - $7.01 Million	149,029 Added 30.16%	643,190 $30.2 Million
Q2 2020 Aug 12, 2020	BUY	$13.0 - $31.0 $1.13 Million - $2.69 Million	86,913 Added 21.34%	494,161 $14.8 Million
Q1 2020 May 12, 2020	BUY	$10.63 - $15.37 $4.33 Million - $6.26 Million	407,248 New	407,248 $5.29 Million

16M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $89.7M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Artisan Partners Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Artisan Partners Limited Partnership with notifications on news.